Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11419565 | PMC |
| http://dx.doi.org/10.1590/0100-3984.2024.57.e5-en | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Treatment algorithm following first-line therapy failure in metastatic prostate cancer].
Urologie
January 2025
Klinik für Urologie, Campus Lübeck, Universitätsklinikum Schleswig-Holstein, Lübeck, Deutschland.
This article provides a comprehensive overview of the current treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC) following the failure of first-line therapy. Although significant progress has been made in the primary treatment of hormone-sensitive prostate cancer, the management of mCRPC remains a clinical challenge. The article outlines the diagnostic criteria for mCRPC, which can be confirmed through biochemical progression and imaging techniques.
View Article and Find Full Text PDFWhich PSMA PET/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study.
BMC Med Imaging
January 2025
Department of Urology, The First Hospital of Shanxi Medical University, Taiyuan, 030000, China.
Background: PSMA PET/CT emerges as a pivotal technology in the diagnostic landscape of prostate cancer (PCa). It offers a suite of imaging interpretation criteria, notably the maximum standardized uptake value (SUVmax), the molecular imaging prostate-specific membrane antigen score (miPSMA score), and the PSMA reporting and data system (PSMA-RADS). Identifying the most valuable criteria for diagnosing PCa and standardizing imaging interpretation across various tracers is an unresolved question.
View Article and Find Full Text PDFDevelopment and validation of biopsy free nomograms for predicting clinically significant prostate cancer in men with PI-RADS 4 and 5 lesions.
Sci Rep
January 2025
Department of Urology, The Second Hospital of Tianjin Medical University, No. 23 Pingjiang Road, Hexi Destrict, Tianjin, 300211, China.
To develop and validate biopsy-free nomograms to more accurately predict clinically significant prostate cancer (csPCa) in biopsy-naïve men with prostate imaging reporting and data system (PI-RADS) ≥ 4 lesions. A cohort of 931 patients with PI-RADS ≥ 4 lesions, undergoing prostate biopsies or radical prostatectomy from January 2020 to August 2023, was analyzed. Various clinical variables, including age, prostate-specific antigen (PSA) levels, prostate volume (PV), PSA density (PSAD), prostate health index (PHI), and maximum standardized uptake values (SUVmax) from PSMA PET-CT imaging, were assessed for predicting csPCa.
View Article and Find Full Text PDFClinical value of a negative [F]F-PSMA PET/CT study in patients diagnosed with prostate cancer treated with prostatectomy with PSA rising below 1 ng/mL after radical prostatectomy, on the outcome of salvage radiotherapy.
Rev Esp Med Nucl Imagen Mol (Engl Ed)
January 2025
ASCIRES-Departamento de Medicina Nuclear del Hospital General Universitario de Valencia.
Objective: To assess the clinical value of [F]F-PSMA negative PET/CT, in patients diagnosed with prostate cancer treated with prostatectomy with elevated PSA less than 1 ng/mL, on the outcome of salvage radiotherapy.
Method: We prospectively included 98 patients diagnosed with prostate cancer treated with prostatectomy with biochemical recurrence [mean PSA 0.51 ng/mL (range 0.
Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer.
J Zhejiang Univ Sci B
January 2025
Department of Orthopedics, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
Prostate cancer is the second most common cancer in men, accounting for 14.1% of new cancer cases in 2020. The aggressiveness of prostate cancer is highly variable, depending on its grade and stage at the time of diagnosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!